Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ANRO

Alto Neuroscience (ANRO)

Alto Neuroscience Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:ANRO
DateTimeSourceHeadlineSymbolCompany
20/06/202422:05Business WireAlto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with SchizophreniaNYSE:ANROAlto Neuroscience Inc
18/06/202422:05Business WireAmit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award WinnerNYSE:ANROAlto Neuroscience Inc
29/05/202422:05Business WireAlto Neuroscience to Present at the Jefferies Global Healthcare ConferenceNYSE:ANROAlto Neuroscience Inc
21/05/202422:29Edgar (US Regulatory)Form 8-K - Current reportNYSE:ANROAlto Neuroscience Inc
21/05/202422:05Business WireAlto Neuroscience Appoints Michael Hanley as Chief Operating OfficerNYSE:ANROAlto Neuroscience Inc
15/05/202406:32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ANROAlto Neuroscience Inc
15/05/202406:25Edgar (US Regulatory)Form 8-K - Current reportNYSE:ANROAlto Neuroscience Inc
15/05/202406:03Business WireAlto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
09/05/202422:05Business WireAlto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific ConferencesNYSE:ANROAlto Neuroscience Inc
23/04/202422:05Business WireAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaNYSE:ANROAlto Neuroscience Inc
03/04/202423:05Business WireAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderNYSE:ANROAlto Neuroscience Inc
22/03/202407:05Business WireAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
11/03/202423:05Business WireAlto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of DirectorsNYSE:ANROAlto Neuroscience Inc
08/03/202400:00Business WireAlto Neuroscience to Participate in Upcoming Investor ConferencesNYSE:ANROAlto Neuroscience Inc
28/02/202400:00Business WireAlto Neuroscience to Present at the TD Cowen 44th Annual Healthcare ConferenceNYSE:ANROAlto Neuroscience Inc
07/02/202408:05Business WireAlto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNYSE:ANROAlto Neuroscience Inc
 Showing the most relevant articles for your search:NYSE:ANRO